Case Report: Inebilizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder with autoimmune diseases: a case series of two patients

Background Neuromyelitis optica spectrum disorder (NMOSD) is a rare spectrum autoimmune disease of the central nervous system, primarily characterized by recurrent episodes of severe optic neuritis and myelitis. Area postrema syndrome (APS) is a common manifestation of NMOSD that is often misdiagnosed initially. Myasthenia gravis (MG) is another uncommon autoimmune disease that occasionally coexists with NMOSD. To date, there are no approved therapies specifically for NMOSD coexists with autoimmune disease. Inebilizumab is a humanized anti-CD19 monoclonal antibody used to treat autoimmune diseases associated with CD19-positive B cells. The first global approval of inebilizumab for the treatment of adult patients with aquaporin-4 antibody (AQP4)-IgG-seropositive NMOSD was announced in June 2020. Case presentation We present two patients with AQP4-IgG-positive NMOSD and coexisting autoimmune disease. One patient presented with APS and coexisting systemic lupus erythematosus (SLE), and the other had established, clinically stable NMOSD and newly diagnosed acetylcholine receptor (AChR)-IgG-positive generalized MG. Both patients showed significant clinical improvement following treatment with inebilizumab, and no relapse has been recorded to date. Conclusion The two cases highlight the potential efficacy of inebilizumab in the treatment of NMOSD. The findings suggest that inebilizumab may be an effective therapeutic option for patients with NMOSD, particularly those who are seropositive for AQP4-IgG or have coexisting autoimmune diseases.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1984033
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Inebilizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder with autoimmune diseases: a case series of two patients

Liu Yang, Zhou Sun, Xianbo Deng, Houying Mu et al.
3 links
Frontiers in Immunology
Multiple Sclerosis Research Studies
article

Case Report: Inebilizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder with autoimmune diseases: a case series of two patients

Liu Yang, Zhou Sun, Xianbo Deng, Houying Mu, Yuanpeng Xia, Zuo-Tian Wu, Zhi Fang, Lei Zhang, Hai Du
article en

Abstract

Background Neuromyelitis optica spectrum disorder (NMOSD) is a rare spectrum autoimmune disease of the central nervous system, primarily characterized by recurrent episodes of severe optic neuritis and myelitis. Area postrema syndrome (APS) is a common manifestation of NMOSD that is often misdiagnosed initially. Myasthenia gravis (MG) is another uncommon autoimmune disease that occasionally coexists with NMOSD. To date, there are no approved therapies specifically for NMOSD coexists with autoimmune disease. Inebilizumab is a humanized anti-CD19 monoclonal antibody used to treat autoimmune diseases associated with CD19-positive B cells. The first global approval of inebilizumab for the treatment of adult patients with aquaporin-4 antibody (AQP4)-IgG-seropositive NMOSD was announced in June 2020. Case presentation We present two patients with AQP4-IgG-positive NMOSD and coexisting autoimmune disease. One patient presented with APS and coexisting systemic lupus erythematosus (SLE), and the other had established, clinically stable NMOSD and newly diagnosed acetylcholine receptor (AChR)-IgG-positive generalized MG. Both patients showed significant clinical improvement following treatment with inebilizumab, and no relapse has been recorded to date. Conclusion The two cases highlight the potential efficacy of inebilizumab in the treatment of NMOSD. The findings suggest that inebilizumab may be an effective therapeutic option for patients with NMOSD, particularly those who are seropositive for AQP4-IgG or have coexisting autoimmune diseases.

Frontiers in ImmunologyVol. 17
Huazhong University of Science and Technology (CN)
National Natural Science Foundation of China, Natural Science Foundation of Hubei Province
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon